

# Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



11<sup>th</sup> August, 2017

To  
**BSE Ltd.**  
Phiroze Jeejeebhoy Towers,  
**Dalal Street,**  
Mumbai – 400 001.

To,  
**National Stock Exchange of India  
Limited**  
“Exchange Plaza”,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

**Scrip Code: 532637**

**Symbol: MANGALAM**

**Sub: Unaudited Financial Results for the Quarter ended on 30<sup>th</sup> June, 2017.**

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2017 along with the Limited Review Report of the said period in the prescribed form which have been taken on record and approved by the Board of Directors of the Company in its meeting held today i.e 11<sup>th</sup> August, 2017 at Mumbai.

Kindly note that the meeting of the Board of Directors commenced at 12.00 p.m and concluded at 02.15 p.m.

Further please note that the company has made necessary arrangement to publish the same in the newspapers as required under the Listing Regulations.

Kindly acknowledge the receipt and take the same in your records.

Thanking You,  
Yours faithfully,  
For Mangalam Drugs & Organics Ltd

*NBavishi*  
  
Nikita Bavishi  
Company Secretary.



**Un-Audited Financial Results for the Quarter Ended 30th June 2017 approved and taken on record by the Board at their meeting dated 11th August,2017**

		(Rs. in Lacs)	
Sr. No.	Particulars	Unaudited	
			Corresponding
		Current Quarter ended 30.06.17	3months ended in the Previous Quarter ended 30.06.16
<b>A PART I - STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017</b>			
1	Revenue from Operations	5970.41	6799.39
2	Other Income	4.41	2.12
3	Total Revenue(1+2)	5974.82	6801.51
4	Expenses		
	(a) Cost of Material Consumed	3971.56	3756.18
	(b) Changes in Inventories of finished goods work in progress and stock in trade	(1405.96)	674.81
	(c) Employee Benefits Expenses	548.99	388.70
	(d) Finance costs	249.84	229.97
	(e) Depreciation	125.32	96.69
	(f) Excise duty & service tax recovered	456.76	102.19
	(g) Other Expenses	1412.52	930.23
	(h) Total Expenses	5359.03	6178.77
5	Profit(+)/Loss before exceptional and extraordinary items and tax (3-4)	615.79	622.74
6	Exceptional Items	0.00	0.00
7	Profit (+) / Loss before extraordinary items and tax (5-6)	615.79	622.74
8	Extraordinary Items	0.00	0.00
9	Profit(+)/Loss before tax (7-8)	615.79	622.74
10	Tax Expenses	200.19	166.45
11	Net Profit(+)/Loss(-) after Tax (9-10)	415.60	456.29
12	Other Comprehensive Income	2.57	3.13
13	Total Comprehensive Income	418.17	459.42
14	Paid up Equity Share Capital (face value Rs.10/-each)	1582.82	1582.82
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00
16	Earning per share (EPS) (of Rs.10/- each) not annualised) :		
	(a) Basic	2.63	2.88
	(b) Diluted	2.63	2.88

**Notes:**

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 11th August,2017.
- The above results have been subjected to Limited Review by Statutory Auditors.
- The Financial results for the quarter ended 30th June,2017 are in compliance with Indian Accounting Standards(Ind-AS) notified by the Ministry of Corporate Affairs. Consequently, result for the corresponding previous quarter ended 30th June 2016 have been restated to comply with Ind-AS to make them comparable.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind-AS 108-Operating Segments.
- From 1st April 2017, Company has adopted accounting standards notified under Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS"). Accordingly the relevant quarterly financial results for the previous corresponding quarter ended 30th June 2016 are restated as per Ind AS. The Reconciliation of Net profit as per Ind AS and previous GAAP ("Accounting Standard") for the relevant corresponding quarter ended 30th June ,2016 is as under :

Particulars	Rs. in Lacs
	Amt
Net Profit as per Accounting Standard	510.25
Employee Benefits - Actuarial Gain/ (Loss) Adjustment	(13.89)
Deferred Tax impact	28.55
Others	(68.62)
Total	(53.96)
Net Profit as per Ind AS	456.29


6 Previous period's figures have been regrouped wherever necessary.

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd.

**Govardhan M. Dhoot**  
Chairman & Managing Director  
DIN:01240086

Place: Mumbai  
Date: 11th August, 2017

For MILWANI ASSOCIATES  
Chartered Accountants







18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.  
Tel. : 22036132 / 9821162679 E-mail: rakesh\_milwani@hotmail.com

Limited Review Report

Review Report to  
The Board of Directors  
**Mangalam Drugs & Organics Limited**

We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs & Organics Limited** for the period ended 30<sup>th</sup> June, 2017 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34, Interim Financial Reporting (Ind AS 34) Prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: **Mumbai**  
Date: 11<sup>th</sup> August, 2017

For Milwani Associates  
Chartered Accountants

  
**RAKESH K MILWANI**  
Proprietor  
Membership No. 36099  
Firm Reg No. 106405W

